CLINICAL STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kidney transplant patients with cancer: drug combo aims to fight tumors without losing the donated kidney
Disease control OngoingThis early-stage study tests whether a mix of three drugs—tacrolimus, nivolumab, and ipilimumab—can shrink or control certain skin cancers in people who have had a kidney transplant. The main goal is to see if the cancer responds without causing the body to reject the transplante…
Matched conditions: CLINICAL STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for Hard-to-Treat merkel cell cancer: drug combo trial underway
Disease control OngoingThis phase 2 trial tests whether adding tuvusertib (a drug that blocks a DNA repair enzyme) to avelumab (an immunotherapy) can slow cancer growth in people with advanced Merkel cell cancer that didn't respond to prior treatment. About 50 participants will receive either the combi…
Matched conditions: CLINICAL STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC